Physician profile
Stacey E Radinsky
NPI 1609829712
$969.98
in general payments reported to CMS, 2019-2025
11 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.89 · 2020: $34.54 · 2021: $324 · 2022: $129 · 2023: $164 · 2024: $144 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.84 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $232.47 | 2021-2024 | Nucala |
| Sanofi-Aventis U.S. LLC | $222.35 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $177.75 | 2024-2025 | Dupixent |
| Genzyme Corporation | $160.16 | 2020-2025 | |
| Alk-Abello, INC | $49.11 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $33.31 | 2022-2024 | Fasenra |
| Kaleo, INC. | $28.07 | 2021 | |
| Genentech USA, INC. | $19.63 | 2019 | |
| Shire North American Group INC | $17.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.86 | 2020 | |
| Amgen INC. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Radinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.